Entrepreneurs Fund
VC Fund
London, United Kingdom
Entrepreneurs Fund is a VC fund in London focused on Biotechnology and Health Care. Entrepreneurs Fund provides early stage and growth financing alongside active support to entrepreneurial teams. Their current areas of investment focus are Life-sciences, Water, Materials and Automotive Technology.
- Total investments:
- 44
- Last investment:
- Lead investor:
- 23%
Last updated:
For AI agents: llms.txt
Industries Entrepreneurs Fund invests in
BiotechnologyHealth CareSoftwareWaterMedical
Stages Entrepreneurs Fund invests in
Series BSeries ASeries CFunding RoundVenture - Series Unknown
Countries Entrepreneurs Fund invests in
United KingdomUnited StatesGermanySwitzerlandIndia
Round sizes
Series A $3.2M–$14MSeries B $3.4M–$22MSeries C $3M–$35M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $3.2M–$14M
- Series B
- $3.4M–$22M
- Series C
- $3M–$35M
Investment Focus
Industry
- Biotechnology 8 (18%)
- Health Care 5 (11%)
- Software 3 (7%)
- Water 2 (5%)
- Medical 2 (5%)
Stage
- Series B 8 (18%)
- Series A 6 (14%)
- Series C 6 (14%)
- Funding Round 6 (14%)
- Venture - Series Unknown 2 (5%)
Country
- United Kingdom 6 (14%)
- United States 5 (11%)
- Germany 3 (7%)
- Switzerland 2 (5%)
- India 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Alexander Hardtmuth
Investment Manager
|
Investment Manager | Total investments: 2 | Find email | |
|
Dennis Brenninkmeijer
Partner
|
Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
General Fusion
|
General Fusion pursues a commercially oriented path toward fusion energy by developing a magnetized target fusion (MTF) technology. The company applies advances in plasma physics, modern electronics, materials, and compression mechanisms to generate fusion-relevant conditions. It operates a demonstration system, Lawson Machine 26 (LM26), thatinjects magnetized plasma into a liquid metal liner and compresses it using coordinated mechanical pistons to reach high temperatures and pressures. The technology serves as a practical stepping stone toward building a fusion demonstration facility and ultimately delivering fusion-derived electricity to the grid. The approach focuses on closing the gap between demonstration milestones and a deployable power-plant system. | $65M / Series E / Dec 16, 2019 | |
Realeyes
|
Realeyes is a leader in computer vision and emotion AI that empowers companies to create remarkable customer experiences that drive growth. Over 150 leading marketers and publishers like Mars Inc., AT&T, Warner Media and Teads rely on Realeyes to measure human response at the speed and scale of AI. | $12.4M / Series B / Jun 06, 2019 | |
|
Realeyes
|
Realeyes is a leader in computer vision and emotion AI that empowers companies to create remarkable customer experiences that drive growth. Over 150 leading marketers and publishers like Mars Inc., AT&T, Warner Media and Teads rely on Realeyes to measure human response at the speed and scale of AI. | $12.4M / Series B / Jun 06, 2019 | |
OptiNose
|
OptiNose develops nasal drug delivery technologies and novel combination drug/device therapies. The drug delivery technologies are based upon a unique and patent-protected principal "Bi-Directional Delivery" which allows drugs to be more efficiently delivered to the nasal cavity. By applying its drug delivery technology, most of thedose is deposited beyond the nasal valve in the upper posterior two-thirds of the nasal cavity, unlike traditional devices. The OptiNose delivery devices have high dose reproducibility and avoid drug deposition to the lungs. In summary, technology fulfills the ideal requirements for nasal drug delivery. Clinical trials have shown that devices can provide a faster onset of action, greater effect with a lower dose, and reduced side effects. The company has offices in Norway and the UK. | $37M / Series D / May 09, 2017 | |
Vasopharm
|
vasopharm is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. In this area, the company is focused on the development of therapeutics influencing the bioavailability of nitric oxide (NO), a cellular signalling moleculeinvolved in many physiological and pathological processes. vasopharm’s drug candidate VAS203 is an allosteric NO synthase inhibitor and represents a completely new class of modulators of nitric oxide synthase (NOS) enzymes. It rapidly lowers excessive NO production in cerebral vessels and tissues, thereby preventing life-threatening increases in intracranial pressure and associated inflammatory processes following traumatic brain injury. | $21.7M / Series G / Jan 21, 2016 | |
Sequana Medical
|
Sequana Medical is a Swiss medical device company providing implantable pump systems to manage fluid balance within the body. This system is designed to move excess fluid to the bladder, where it is passed naturally from the body through normal urination.Sequana Medical’s first product, the Alfapump System, is an innovative solution for themanagement of ascites. Ascites is a fluid that collects in the abdominal cavity in people with advanced liver disease, certain cancers, or congestive heart failure. Alfapump System was the first and only system for the automatic and continual removal of ascites.Sequana Medical was founded in 2006 and is based in Zurich, Switzerland. | $10.5M / Series C / Oct 23, 2015 | |
|
General Fusion
|
General Fusion pursues a commercially oriented path toward fusion energy by developing a magnetized target fusion (MTF) technology. The company applies advances in plasma physics, modern electronics, materials, and compression mechanisms to generate fusion-relevant conditions. It operates a demonstration system, Lawson Machine 26 (LM26), thatinjects magnetized plasma into a liquid metal liner and compresses it using coordinated mechanical pistons to reach high temperatures and pressures. The technology serves as a practical stepping stone toward building a fusion demonstration facility and ultimately delivering fusion-derived electricity to the grid. The approach focuses on closing the gap between demonstration milestones and a deployable power-plant system. | $22.1M / Venture - Series Unknown / May 19, 2015 | |
D3O
|
D3O is a ground breaking impact protection solutions company that licenses a range of unique patented smart materials. This market changing technology is used to produce a shock absorbing material which can be found in a range of products across the motorcycle, sport, footwear, electronics, military and workwear sectors.D3O® was proven duringthe 2006 Winter Olympics, when the US and Canadian ski teams pioneered D3O®’s revolutionary soft armour. With no compromise on protection, D3O overnight changed the global protective wear market with a range of low profile, light weight, flexible and breathable limb protectors. Today, D3O leads and challenges the world of impact protection and shock absorption with innovative pioneering solutions for its customers. | $19.3M / Venture - Series Unknown / Apr 07, 2015 | |
Exosect
|
Exosect was established in 2001 as a spin-out from the University of Southampton to develop a platform technology and range of natural bio-control products for the protection of food from pests and disease. Having developed the technology, gained 41 patents and 28 national product registrations and successfully test-marketed the technology andproducts, the Company is well-positioned to commercialise its unique patented platform technology across the food supply chain. | $2.4M / Venture - Series Unknown / Jan 16, 2015 | |
Rakuten Fits Me
|
Fit Origin is the ultimate fit recommendation solution for eCommerce fashion retailers which puts fit and body shapes at the heart of the online shopping experience. It combines garment data and shopper data to determine which size garment will fit them, the way they want to wear it.Each shopper’s measurements are calculated based on height,weight, age and body shape. Deep statistical analysis of thousands of detailed body scans allows their data scientists to use these limited data points to infer high quality information about the shopper’s measurements.Every garment is analysed by their garment technologists, taking many factors into account including silhouette, stretch and fit preference. A shopper’s body measurements are used in conjunction with garment measurements to interpret how each size will fit a shopper.Fit Origin recommends the best size to fit shoppers, with the ability to compare sizes based on their own fit preferences.Their fit recommendation solution allows your shoppers to buy with confidence. At Rakuten Fits Me they are all about ‘Me’ fashion, not mass fashion. They are the only size and fit solution provider to align your product data with shopper body data so they get the perfect fit, first time, every time. | $5.3M / Oct 24, 2014 | |
| See all 44 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
SaaS Investors
112,472 investors
Software Investors
55,440 investors
Health Care Investors
47,147 investors
Climate Investors
43,790 investors
Energy Investors
26,945 investors
Biotech Investors
23,541 investors
Biotechnology Investors
20,889 investors
Medical Investors
20,530 investors
SaaS VC Funds
69,112 investors
FAQ
What does Entrepreneurs Fund invest in?
Entrepreneurs Fund invests primarily in Biotechnology, Health Care and Software startups, most often at Series B and Series A stage. Most of the 44 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Entrepreneurs Fund's check size?
Entrepreneurs Fund typically joins rounds of $3.2M–$14M at Series A, $3.4M–$22M at Series B and $3M–$35M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Entrepreneurs Fund participates in.
How do I contact Entrepreneurs Fund?
Public channels for Entrepreneurs Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Entrepreneurs Fund?
The team at Entrepreneurs Fund includes Alexander Hardtmuth (Investment Manager) and Dennis Brenninkmeijer (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
